Efficacy and Safety of DCAG Regimen in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2025.01.002
- Author:
Hui-Sheng ZHOU
1
;
Yu-Qing LI
1
;
Yu-Xin WANG
1
;
Ya-Lei HU
1
;
Kai-Li MIN
1
;
Chun-Ji GAO
1
;
Dai-Hong LIU
1
;
Xiao-Ning GAO
1
Author Information
1. Senior Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China.
- Publication Type:Journal Article
- Keywords:
relapsed； refractory； acute myeloid leukemia； DCAG regimen
- MeSH:
Humans;
Leukemia, Myeloid, Acute/drug therapy*;
Cytarabine/administration & dosage*;
Granulocyte Colony-Stimulating Factor/administration & dosage*;
Retrospective Studies;
Male;
Female;
Decitabine;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Anthracyclines/administration & dosage*;
Middle Aged;
Adult;
Treatment Outcome;
Aged;
Recurrence
- From:
Journal of Experimental Hematology
2025;33(1):9-19
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the efficacy and safety of DCAG (decitabine, cytarabine, anthracyclines, and granulocyte colony-stimulating factor) regimen in the treatment of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).
METHODS:The clinical data of 64 R/R AML patients received treatment at Chinese PLA General Hospital from January 1st, 2012 to December 31st, 2022 were retrospectively analyzed. Primary endpoints included efficacy measured by overall response rate (ORR) and safety. Secondary endpoints included overall survival (OS), event-free survival (EFS) and duration of response (DOR). The patients were followed from enrollment until death, or the end of last follow-up (June 1st, 2023), whichever occurred first.
RESULTS:Sixty-four patients who failed prior therapy were enrolled and completed 1 cycle, and 26 and 5 patients completed 2 and 3 cycles, respectively. Objective response rate was 67.2% ［39: complete remission (CR)/CR with incomplete hematologic recovery (CRi), 4: partial remission (PR)］. With a median follow-up of 62.0 months (1.0-120.9), the median overall survival (OS) was 23.3 and event-free survival was 10.6 months. The median OS was 51.7 months (3.4-100.0) in responders (CR/CRi/PR) while it was 8.4 months (6.1-10.7) in nonresponders ( P <0.001). Grade 3-4 hematologic toxicities were observed in all patients. Four patients died from rapid disease progression within 8 weeks after chemotherapy.
CONCLUSION:The DCAG regimen represents a feasible and effective treatment for R/R AML.
